Sung Won Song
Director/Board Member bij JW (CAYMAN) THERAPEUTICS CO. LTD
Profiel
Sung Won Song is currently a Director at EpimAb Biotherapeutics, Inc. and a Non-Executive Director at JW (Cayman) Therapeutics Co. Ltd.
Dr. Song has a graduate degree from The Trustees of Columbia University in The City of New York, a doctorate degree from The Ohio State University, and an undergraduate degree from Korea University.
Actieve functies van Sung Won Song
Bedrijven | Functie | Begin |
---|---|---|
JW (CAYMAN) THERAPEUTICS CO. LTD | Director/Board Member | 29-08-2023 |
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Director/Board Member | - |
Opleiding van Sung Won Song
The Trustees of Columbia University in The City of New York | Graduate Degree |
The Ohio State University | Doctorate Degree |
Korea University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
JW (CAYMAN) THERAPEUTICS CO. LTD | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |